LBPH vs. SCTL, MLTX, MOR, AGIO, RNA, GPCR, TGTX, ACAD, INDV, and RYTM
Should you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Societal CDMO (SCTL), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Agios Pharmaceuticals (AGIO), Avidity Biosciences (RNA), Structure Therapeutics (GPCR), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Indivior (INDV), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical preparations" industry.
Societal CDMO (NASDAQ:SCTL) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.
Longboard Pharmaceuticals has a net margin of 0.00% compared to Longboard Pharmaceuticals' net margin of -14.03%. Longboard Pharmaceuticals' return on equity of -23.82% beat Societal CDMO's return on equity.
In the previous week, Longboard Pharmaceuticals had 3 more articles in the media than Societal CDMO. MarketBeat recorded 3 mentions for Longboard Pharmaceuticals and 0 mentions for Societal CDMO. Societal CDMO's average media sentiment score of 1.18 beat Longboard Pharmaceuticals' score of 0.00 indicating that Longboard Pharmaceuticals is being referred to more favorably in the news media.
Longboard Pharmaceuticals received 36 more outperform votes than Societal CDMO when rated by MarketBeat users. However, 80.00% of users gave Societal CDMO an outperform vote while only 73.33% of users gave Longboard Pharmaceuticals an outperform vote.
Societal CDMO has higher revenue and earnings than Longboard Pharmaceuticals. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Societal CDMO, indicating that it is currently the more affordable of the two stocks.
Societal CDMO currently has a consensus price target of $1.80, indicating a potential upside of 63.64%. Longboard Pharmaceuticals has a consensus price target of $43.67, indicating a potential upside of 141.12%. Given Societal CDMO's stronger consensus rating and higher possible upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Societal CDMO.
Societal CDMO has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.
87.2% of Societal CDMO shares are owned by institutional investors. Comparatively, 63.3% of Longboard Pharmaceuticals shares are owned by institutional investors. 7.6% of Societal CDMO shares are owned by insiders. Comparatively, 4.6% of Longboard Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Societal CDMO beats Longboard Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Longboard Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longboard Pharmaceuticals Competitors List
Related Companies and Tools
